Management of Venous Thromboembolic Disease in Childhood

Deep Vein Thrombosis and Pulmonary Embolism

Volumn , Issue , 2009, Pages 373-404

  Van Ommen, C Heleen ^a   Heijboer, Harriet ^a   Peters, Marjolein ^a  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Antithrombotic therapy; Central venous catheter; Diagnosis; Outcome; Paediatric; Prophylaxis; Risk factors; Venous thromboembolic disease

Indexed keywords

EID: 84889774222     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470745007.ch17     Document Type: Chapter

References (167)

1. Andrew M, David M, Adams M, Ali K, Anderson R, Barnard D, et al . Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994; 83: 1251-7.
2. Nordström M, Lindblad B, Bergqvist D, Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232:155-60.
3. Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry. Paediatrics 1995; 96:939-43.
4. Van Ommen CH, Heijboer H, Büller HR, Hirasing RA, Heijmans HS, Peters M. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr 2001; 139:676-81.
5. Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost 2005; 3: 1611-7.
6. Buck JR, Connors RH, Coon WW, Weintraub WH, Wesley JR, Coran AG. Pulmonary embolism in children. J Pediatr Surg 1981; 16:385-91.
7. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood 1992; 80:1998-2005.
8. White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107 (Suppl 1):I4-I8.
9. Chalmers EA. Epidemiology of venous thromboembolism in neonates and children. Thromb Res 2006; 118:3-12.
10. Virchow R. Phlogose and Thrombose im Gef̈asssystem. In Virchow R (ed), Gesammelte Abhandlungen zur Wissenschaftlichen Medizin. Von Meidinger Sohn, Frankfurt, 1856, pp. 458-636.
11. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158:585-93.
12. White RH, Zhou H, Romano PS. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med 1998; 128:737-40.
13. Manco-Johnson MJ. Etiopathogenesis of paediatric thrombosis. Hematology 2005; 10(Suppl 1):167-70.
14. Nowak-Göttl U, von Kries R, Göbel U. Neonatal symptomatic thromboembolism in Germany: two year survey. Arch Dis Child Fetal Neonatal Ed 1997; 76:F163-F167.
15. van Ommen CH, Heijboer H, van den Dool EJ, Hutten BA, Peters M. Paediatric venous thromboembolic disease in one single centre: congenital prothrombotic disorders and the clinical outcome. J Thromb Haemost 2003; 1:2516-22.
16. Journeycake JM, Buchanan GR. Thrombotic complications of central venous catheters in children. Curr Opin Hematol 2003; 10:369-74.
17. Andrew M, Marzinotto V, Pencharz P, Zlotkin S, Burrows P, Ingram J, et al . A cross-sectional study of catheter-related thrombosis in children receiving total parenteral nutrition at home. J Pediatr 1995; 126:358-63.
18. Miga DE, McKellar LF, Denslow S, Wiles HB, Case CL, Gillette PC. Incidence of femoral vein occlusion after catheter ablation in children: evaluation with magnetic resonance angiography. Pediatr Cardiol 1997; 18:204-7.
19. Journeycake JM, Buchanan GR. Catheter-related deep venous thrombosis and other catheter complications in children with cancer. J Clin Oncol 2006; 24:4575-80.
20. Ingram J, Weitzman S, Greenberg ML, Parkin P, Filler R. Complications of indwelling venous access lines in the paediatric hematology patient: a prospective comparison of external venous catheters and subcutaneous ports. Am J Pediatr Hematol Oncol 1991; 13:130-6.
21. Male C, Chait P, Andrew M, Hanna K, Julian J, Mitchell L. Central venous line-related thrombosis in children: association with central venous line location and insertion technique. Blood 2003; 101:4273-8.
22. Mitchell LG, Andrew M, Hanna K, Abshire T, Halton J, Anderson R, et al A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with l-asparaginase - Results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) study. Cancer 2003; 97:508-16.
23. Pierce CM, Wade A, Mok Q. Heparin-bonded central venous lines reduce thrombotic and infective complications in critically ill children. Intensive Care Med 2000; 26:967-72.
24. Ruud E, Natvig S, Holmstrom H, Wesenberg F. Low prevalence of femoral venous thrombosis after cardiac catheterizations in children: a prospective study. Cardiol Young 2002; 12:513-8.
25. Massicotte P, Julian JA, Gent M, Shields K, Marzinotto V, Szechtman B,et al . An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thromb Res 2003; 109:101-8.
26. Massicotte MP, Dix D, Monagle P, Adams M, Andrew M. Central venous catheter related thrombosis in children: analysis of the Canadian Registry of Venous Thromboembolic Complications. J Pediatr 1998; 133:770-6.
27. Perloff JK. Longevity in congenital heart disease: a tribute to paediatric cardiology. J Pediatr 1993; 122:S49-S58.
28. Petaja J, Lundstrom U, Sairanen H, Marttinen E, Griffin JH. Central venous thrombosis after cardiac operations in children. J Thorac Cardiovasc Surg 1996; 112:883-9.
29. Monagle P, Karl TR. Thromboembolic problems after the Fontan operation. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2002; 5:36-47.
30. Berman W Jr, Fripp RR, Yabek SM, Wernly J, Corlew S. Great vein and right atrial thrombosis in critically ill infants and children with central venous lines. Chest 1991; 99:963-7.
31. Monagle P, Cochrane A, McCrindle B, Benson L, Williams W, Andrew M. Thromboembolic complications after fontan procedures - the role of prophylactic anticoagulation. J Thorac Cardiovasc Surg 1998; 115:493-8.
32. Cromme-Dijkhuis AH, Henkens CM, Bijleveld CM, Hillege HL, Bom VJ, van der Meer J. Coagulation factor abnormalities as possible thrombotic risk factors after Fontan operations. Lancet 1990; 336:1087-90.
33. Jahangiri M, Shore D, Kakkar V, Lincoln C, Shinebourne E. Coagulation factor abnormalities after the Fontan procedure and its modifications. J Thorac Cardiovasc Surg 1997; 113:989-92.
34. Odegard KC, McGowan FX Jr, DiNardo JA, Castro RA, Zurakowski D, Connor CM,et al . Coagulation abnormalities in patients with single-ventricle physiology precede the Fontan procedure. J Thorac Cardiovasc Surg 2002; 123:459-65.
35. Odegard KC, McGowan FX Jr, Zurakowski D, DiNardo JA, Castro RA, del Nido PJ, et al . Procoagulant and anticoagulant factor abnormalities following the Fontan procedure: increased factor VIII may predispose to thrombosis. J Thorac Cardiovasc Surg 2003; 125:1260-7.
36. Giannakopoulos B, Passam F, Rahgozar S, Krilis SA. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 2007; 109:422-30.
37. Male C, Foulon D, Hoogendoorn H, Vegh P, Silverman E, David M, et al . Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in paediatric patients with systemic lupus erythematosus. Blood 2005; 106:4152-8.
38. Levy DM, Massicotte MP, Harvey E, Hebert D, Silverman ED. Thromboembolism in paediatric lupus patients. Lupus 2003; 12:741-6.
39. Berkun Y, Padeh S, Barash J, Uziel Y, Harel L, Mukamel M, et al . Antiphospholipid syndrome and recurrent thrombosis in children. Arthritis Rheum 2006; 55:850-5.
40. Campos LM, Kiss MH, D'Amico EA, Silva CA. Antiphospholipid antibodies in 57 children and adolescents with systemic lupus erythematosus. Rev Hosp Clin Fac Med Sao Paulo 2003; 58:157-62.
41. Knöfler R, Siegert E, Lauterbach I, Taut-Sack H, Siegert G, Gehrisch S, et al . Clinical importance of prothrombotic risk factors in paediatric patients with malignancy - impact of central venous lines. Eur J Pediatr 1999; 158:S147-S150.
42. Wermes C, von Depka P, Lichtinghagen R, Barthels M, Welte K, Sykora KW. Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters. Eur J Pediatr 1999; 158:S143-S146.
43. Glaser DW, Medeiros D, Rollins N, Buchanan GR. Catheter-related thrombosis in children with cancer. J Pediatr 2001; 138:255-9.
44. Ruud E, Holmstrom H, Natvig S, Wesenberg F. Prevalence of thrombophilia and central venous catheter-associated neck vein thrombosis in 41 children with cancer-a prospective study. Med Pediatr Oncol 2002; 38:405-10.
45. Santoro N, Giordano P, Del Vecchio GC, Guido G, Rizzari C, Varotto S, et al . Ischemic stroke in children treated for acute lymphoblastic leukemia: a retrospective study. J Pediatr Hematol Oncol 2005; 27:153-7.
46. Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Mariani G, de Gaetano G, et al . Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 paediatric patients. Blood 2006; 108:2216-22.
47. Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. Thromb Res 2003; 111:199-212.
48. Weimann E, Brack C. Severe thrombosis during treatment with ethinylestradiol for tall stature. Horm Res 1996; 45:261-3.
49. Werder EA, Waibel P, Sege D, Flury R. Severe thrombosis during oestrogen treatment for tall stature. Eur J Pediatr 1990; 149:389-90.
50. van Ommen CH, Fijnvandraat K, Vulsma T, Delemarre-Van De Waal HA, Peters M. Acquired protein S deficiency caused by estrogen treatment of tall stature. J Pediatr 1999; 135:477-81.
51. D'Angelo A, Mazzola G, Vigano D'Angelo S. High prevalence of severe, transient autoimmune protein s deficiency in young patients with purpura fulminans or extensive venous thromboembolism associated with varicella infection. Thromb Haemost 1999; 80(Suppl):427.
52. Levin M, Eley BS, Louis J, Cohen H, Young L, Heyderman RS. Postinfectious purpura fulminans caused by an autoantibody directed against protein S. J Pediatr 1995; 127:355-63.
53. van Ommen CH, van Wijnen M, de Groot FG, van der Horst CM, Peters M. Postvaricella purpura fulminans caused by acquired protein s deficiency resulting from antiprotein s antibodies: search for the epitopes. J Pediatr Hematol Oncol 2002; 24:413-6.
54. Arnoux JB, Boddaert N, Valayannopoulos V, Romano S, Bahi-Buisson N, Desguerre I,et al. Risk assessment of acute vascular events in congenital disorder of glycosylation type Ia. Mol Genet Metab 2008; 93:444-9.
55. Fiumara A, Barone R, Buttitta P, Musso R, Pavone L, Nigro F,et al . Haemostatic studies in carbohydrate-deficient glycoprotein syndrome type I. Thromb Haemost 1996; 76:502-4.
56. Young G, Driscoll MC. Coagulation abnormalities in the carbohydrate-deficient glycoprotein syndrome: case report and review of the literature. Am J Hematol 1999; 60:66-9.
57. van Ommen CH, Peters M, Barth PG, Vreken P, Wanders RJ, Jaeken J. Carbohydrate-deficient glycoprotein syndrome type 1a: a variant phenotype with borderline cognitive dysfunction, cerebellar hypoplasia and coagulation disturbances. J Pediatr 2000; 136:400-3.
58. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13:516-30.
59. Heit JA. Thrombophilia: common questions on laboratory assessment and management. Hematology Am Soc Hematol Educ Program 2007; 2007:127-35.
60. Bonduel M, Hepner M, Sciuccati G, Torres AF, Pieroni G, Frontroth JP. Prothrombotic abnormalities in children with venous thromboembolism. J Pediatr Hematol Oncol 2000; 22:66-72.
61. Bonduel M, Hepner M, Sciuccati G, Pieroni G, Feliu-Torres A, Mardaraz C,et al . Factor V Leiden and prothrombin gene G20210A mutation in children with venous thromboembolism. Thromb Haemost 2002; 87:972-7.
62. Ehrenforth S, Junker R, Koch HG, Kreuz W, Münchow N, Scharrer I,et al . Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood. Childhood Thrombophilia Study Group. Eur J Pediatr 1999; 158:S97-S104.
63. Junker R, Koch HG, Auberger K, Münchow N, Ehrenforth S, Nowak-Göttl U. Prothrombin G20210A gene mutation and further prothrombotic risk factors in childhood thrombophilia. Arterioscler Thromb Vasc Biol 1999; 19:2568-72.
64. Kosch A, Junker R, Kurnik K, Schobess R, Günther G, Koch H,et al . Prothrombotic risk factors in children with spontaneous venous thrombosis and their asymptomatic parents: a family study. Thromb Res 2000; 99:531-7.
65. Lawson SE, Butler D, Enayat MS, Williams MD. Congenital thrombophilia and thrombosis: a study in a single centre. Arch Dis Child 1999; 81:176-8.
66. Nowak-Göttl U, Junker R, Kreuz W, von Eckardstein A, Kosch A, Nohe N,et al . Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 2001; 97:858-62.
67. Salonvaara M, Riikonen P, Kekom̈aki R, Heinonen K. Clinically symptomatic central venous catheter-related deep venous thrombosis in newborns. Acta Paediatr 1999; 88:642-6.
68. Schobess R, Junker R, Auberger K, Münchow N, Burdach S, Nowak-Göttl U. Factor V G1691A and prothrombin G20210A in childhood spontaneous venous thrombosis - evidence of an age-dependent thrombotic onset in carriers of factor V G1691A and prothrombin G20210A mutation. Eur J Pediatr 1999; 158:S105-S108.
69. Koster T, Rosendaal FR, Reitsma PH, van der Velden, Brïet E, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms - the Leiden Thrombophilia Study (LETS). Thromb Haemost 1994; 71:719-22.
70. Koster T, Blann AD, Brïet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345:152-5.
71. Meijers JCM, Tekelenburg WLH, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000; 342:696-701.
72. van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood 2000; 95:3678-82.
73. van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95:2855-9.
74. den Heyer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost 2005; 3:292-9.
75. Bezemer ID, Bare LA, Doggen CJ, Arellano AR, Tong C, Rowland CM,et al . Gene variants associated with deep vein thrombosis. JAMA 2008; 299:1306-14.
76. Revel-Vilk S, Chan A, Bauman M, Massicotte P. Prothrombotic conditions in an unselected cohort of children with venous thromboembolic disease. J Thromb Haemost 2003; 1:915-21.
77. Middeldorp S, Henkens CM, Koopman MM, van Pampus EC, Hamulyak K, van der Meer J, et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med 1998; 128:15-20.
78. Middeldorp S, Meinardi JR, Koopman MM, van Pampus EC, Hamulyak K, van der Meer J,et al. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med 2001; 135:322-7.
79. Simioni P, Sanson BJ, Prandoni P, Tormene D, Friederich PW, Girolami B, et al . Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81:198-202.
80. Tormene D, Simioni P, Prandoni P, Franz F, Zerbinati P, Tognin G, et al . The incidence of venous thromboembolism in thrombophilic children: a prospective cohort study. Blood 2002; 100:2403-5.
81. Bank I, Scavenius MP, Büller HR, Middeldorp S. Social aspects of genetic testing for factor V Leiden mutation in healthy individuals and their importance for daily practice. Thromb Res 2004; 113:7-12.
82. Legnani C, Razzaboni E, Gremigni P, Ricci Bitti PE, Favaretto E, Palareti G. Psychological impact of testing for thrombophilic alterations. Thromb Haemost 2006; 96:348-55.
83. Marchetti M, Quaglini S, Barosi G. Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A. QJM 2001; 94:365-72.
84. Wu O, Robertson L, Twaddle S, Lowe GD, Clark P, Greaves M, et al . Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess 2006; 10:1-110.
85. Kurekci E, Kaye R, Koehler M. Chylothorax and chylopericardium: a complication of a central venous catheter. J Pediatr 1998; 132:1064-6.
86. Mulvihill SJ, Fonkalsrud EW. Complications of superior versus inferior vena cava occlusion in infants receiving central total parenteral nutrition. J Pediatr Surg 1984; 19:752-7.
87. Bernstein D, Coupey S, Schonberg SK. Pulmonary embolism in adolescents. Am J Dis Child 1986; 140:667-71.
88. van Ommen CH, Heyboer H, Groothoff JW, Teeuw R, Aronson DC, Peters M. Persistent tachypnea in children: keep pulmonary embolism in mind. J Pediatr Hematol Oncol 1998; 20:570-3.
89. Derish MT, Smith DW, Frankel LR. Venous catheter thrombus formation and pulmonary embolism in children. Pediatr Pulmonol 1995; 20:349-54.
90. Miniati M, Prediletto R, Formichi B, Marini C, Di Ricco G, Tonelli L, et al . Accuracy of clinical assessment in the diagnosis of pulmonary embolism. Am J Respir Crit Care Med 1999; 159:864-71.
91. Wells PS, Anderson DR, Rodger M, Ginsberg JS, Kearon C, Gent M, et al . Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 2000; 83:416-20.
92. Wells PS, Anderson DR, Rodger M, Stiell I, Dreyer JF, Barnes D, et al . Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and D-dimer. Ann Intern Med 2001; 135:98-107.
93. Wicki J, Perneger TV, Junod AF, Bounameaux H, Perrier A. Assessing clinical probability of pulmonary embolism in the emergency ward: a simple score. Arch Intern Med 2001; 161:92-7.
94. de Groot MR, van Marwijk Kooy M, Pouwels JG, Engelage AH, Kuipers BF, Büller HR. The use of a rapid D-dimer blood test in the diagnostic work-up for pulmonary embolism: a management study. Thromb Haemost 1999; 82:1588-92.
95. Male C, Chait P, Ginsberg JS, Hanna K, Andrew M, Halton J, et al . Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children: results of the PARKAA study. Prophylactic Antithrombin Replacement in Kids with ALL treated with Asparaginase. Thromb Haemost 2002; 87:593-8.
96. Goodacre S, Sampson F, Thomas S, van Beek E, Sutton A. Systematic review and meta-analysis of the diagnostic accuracy of ultrasonography for deep vein thrombosis. BMC Med Imaging 2005; 5:6.
97. Miniati M, Pistolesi M, Marini C, Di RG, Formichi B, Prediletto R, et al . Value of perfusion lung scan in the diagnosis of pulmonary embolism: results of the Prospective Investigative Study of Acute Pulmonary Embolism Diagnosis (PISA-PED). Am J Respir Crit Care Med 1996; 154:1387-93.
98. Moores LK, Jackson WL Jr, Shorr AF, Jackson JL. Meta-analysis: outcomes in patients with suspected pulmonary embolism managed with computed tomographic pulmonary angiography. Ann Intern Med 2004; 141:866-74.
99. Daftary A, Gregory M, Daftary A, Seibyl JP, Saluja S. Chest radiograph as a triage tool in the imaging-based diagnosis of pulmonary embolism. AJR Am J Roentgenol 2005; 185:132-4.
100. Shah PS, Kalyn A, Satodia P, Dunn MS, Parvez B, Daneman A, et al . A randomized, controlled trial of heparin versus placebo infusion to prolong the usability of peripherally placed percutaneous central venous catheters (PCVCs) in neonates: the HIP (Heparin Infusion for PCVC) study. Paediatrics 2007; 119:e284-e291.
101. Kakzanov V, Monagle P, Chan AK. Thromboembolism in infants and children with gastrointestinal failure receiving long-term parenteral nutrition. JPEN J Parenter Enteral Nutr 2008; 32:88-93.
102. Newall F, Barnes C, Savoia H, Campbell J, Monagle P. Warfarin therapy in children who require long-term total parenteral nutrition. Paediatrics 2003; 112:e386-e388.
103. Krafte-Jacobs B, Sivit CJ, Mejia R, Pollack MM. Catheter-related thrombosis in critically ill children: comparison of catheters with and without heparin bonding. J Pediatr 1995; 126:50-4.
104. Anton N, Cox P, Massicotte P, Dinyari M, Vegh P, Mitchell LG. No difference in incidences of thrombosis between heparin bonded catheters and non heparin bonded catheters in infants in the critical care unit following surgery for congenital heart disease: a randomised controlled triple blind study (abstract). J Thromb Haemost 2005; 3 (Suppl 1):P1726.
105. Shah PS, Shah N. Heparin-bonded catheters for prolonging the patency of central venous catheters in children. Cochrane Database Syst Rev 2007; (4):CD005983.
106. Mitchell L, Andrew M, Hanna K, Abshire T, Halton J, Wu J, et al . Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia - Results of the PARKAA study. Thromb Haemost 2003; 90:235-44.
107. Ruud E, Holmstrom H, de Lange C, Hogstad EM, Wesenberg F. Low-dose warfarin for the prevention of central line-associated thromboses in children with malignancies - a randomized, controlled study. Acta Paediatr 2006; 95:1053-9.\
108. Elhasid R, Lanir N, Sharon R, Weyl Ben AM, Levin C, Postovsky S, et al . Prophylactic therapy with enoxaparin during l-asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrinol 2001; 12:367-70.
109. Hettiarachchi RJ, Prins MH, Lensing AW, Büller HR. Low molecular weight heparin versus unfractionated heparin in the initial treatment of venous thromboembolism. Curr Opin Pulm Med 1998; 4:220-5.
110. Gibson BE, Chalmers E, Bolton-Maggs P, Henderson DJ, Lynn R. Thromboembolism in childhood: a prospective two year BPSU study in the United Kingdom. February 2001-February 2003. J Thromb Haemost 2003 1 (Suppl.1):OC422.
111. Massicotte P, Julian JA, Gent M, Shields K, Marzinotto V, Szechtman B, et al . An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thromb Res 2003; 109:85-92.
112. Kuhle S, Massicotte P, Dinyari M, Vegh P, Mitchell D, Marzinotto V, et al . Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in paediatric patients with thromboembolic events. Thromb Haemost 2005; 94:1164-71.
113. Massicotte P, Adams M, Marzinotto V, Brooker LA, Andrew M. Low-molecular-weight heparin in paediatric patients with thrombotic disease: a dose finding study. J Pediatr 1996; 128:313-8.
114. Massicotte P, Julian JA, Marzinotto V, Gent M, Shields K, Chan AK, et al . Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin-sodium) in paediatric patients. Thromb Res 2003; 109:93-9.
115. Michaels LA, Gurian M, Hegyi T, Drachtman RA. Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant. Paediatrics 2004; 114:703-7.
116. Nohe N, Flemmer A, Rumler R, Praun M, Auberger K. The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases. Eur J Paediatr 1999; 158:S134-S139.
117. van Ommen CH, van den Dool EJ, Peters M. Nadroparin therapy in paediatric patients with venous thromboembolic disease. J Pediatr Hematol Oncol 2008; 30:230-4.
118. Sutor AH, Chan AKC, Massicotte P. Low-molecular-weight heparin in paediatric patients. Semin Thromb Hemost 2004; 30:31-9.
119. Andrew M, Marzinotto V, Brooker LA, Adams M, Ginsberg J, Freedom R, et al . Oral anticoagulation therapy in paediatric patients: a prospective study. Thromb Haemost 1994; 71:265-9.
120. Andrew M, Marzinotto V, Massicotte P, Blanchette V, Ginsberg J, Brill-Edwards P, et al . Heparin therapy in paediatric patients: a prospective cohort study. Pediatr Res 1994; 35:78-83.
121. Laporte S, Mismetti P, Piquet P, Doubine S, Touchot A, Decousus H. Population pharmacokinetic of nadroparin calcium (Fraxiparine) in children hospitalised for open heart surgery. Eur J Pharm Sci 1999; 8:119-25.
122. Mismetti P, Laporte-Simitsidis S, Navarro C, Sie P, d'Azemar P, Necciari J, et al . Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin). Thromb Haemost 1998; 79:1162-5.
123. Ignjatovic V, Summerhayes R, Than J, Gan A, Monagle P. Therapeutic range for unfractionated heparin therapy: age-related differences in response in children. J Thromb Haemost 2006; 4:2280-2.
124. Kuhle S, Eulmesekian P, Kavanagh B, Massicotte P, Vegh P, Mitchell LG. A clinically significant incidence of bleeding in critically ill children receiving therapeutic doses of unfractionated heparin: a prospective cohort study. Haematologica 2007; 92:244-7.
125. Risch L, Huber AR, Schmugge M. Diagnosis and treatment of heparin-induced thrombocytopenia in neonates and children. Thromb Res 2006; 118:123-35.
126. Goldenberg NA, Durham JD, Knapp-Clevenger R, Manco-Johnson MJ. A thrombolytic regimen for high-risk deep venous thrombosis may substantially reduce the risk of postthrombotic syndrome in children. Blood 2007; 110:45-53.
127. Monagle P, Chan A, Massicotte P, Chalmers E, Michelson AD. Antithrombotic therapy in children: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl):645S-687S.
128. Ouriel K. Comparison of safety and efficacy of the various thrombolytic agents. Rev Cardiovasc Med 2002; 3 (Suppl 2):S17-S24.
129. Chalmers EA, Gibson BE. Thrombolytic therapy in the management of paediatric thromboembolic disease. Br J Haematol 1999; 104:14-21.
130. Gupta AA, Leaker M, Andrew M, Massicotte P, Liu L, Benson LN, et al . Safety and outcomes of thrombolysis with tissue plasminogen activator for treatment of intravascular thrombosis in children. J Pediatr 2001; 139:682-8.
131. Knöfler R, Dinger J, Kabus M, Müller D, Lauterbach I, Rupprecht E, et al . Thrombolytic therapy in children - clinical experiences with recombinant tissue-plasminogen activator. Semin Thromb Hemost 2001; 27:169-74.
132. Nowak-Gottl U, Auberger K, Halimeh S, Junker R, Klinge J, Kreuz WD, et al . Thrombolysis in newborns and infants. Thromb Haemost 1999; 82(Suppl 1):112-6.
133. Wang M, Hays T, Balasa V, Bagatell R, Gruppo R, Grabowski EF, et al . Low-dose tissue plasminogen activator thrombolysis in children. J Pediatr Hematol Oncol 2003; 25:379-86.
134. Bonduel M, Sciuccati G, Hepner M, Torres AF, Pieroni G, Frontroth JP, et al . Acenocoumarol therapy in paediatric patients. J Thromb Haemost 2003; 1:1740-3.
135. Streif W, Andrew M, Marzinotto V, Massicotte P, Chan AKC, Julian JA, et al . Analysis of warfarin therapy in paediatric patients: a prospective cohort study of 319 patients. Blood 1999; 94:3007-14.
136. Marzinotto V, Monagle P, Chan A, Adams M, Massicotte P, Leaker M, et al . Capillary whole blood monitoring of oral anticoagulants in children in outpatient clinics and the home setting. Pediatr Cardiol 2000; 21:347-52.
137. Massicotte P, Marzinotto V, Vegh P, Adams M, Andrew M. Home monitoring of warfarin therapy in children with a whole blood prothrombin time monitor. J Pediatr 1995; 127:389-94.
138. Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl):401S-428S.
139. Weitz JI, Linkins LA. Beyond heparin and warfarin: the new generation of anticoagulants. Expert Opin Invest Drugs 2007; 16:271-82.
140. Gross PL, Weitz JI. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol 2008; 28:380-6.
141. Risch L, Fischer JE, Herklotz R, Huber AR. Heparin-induced thrombocytopenia in paediatrics: clinical characteristics, therapy and outcomes. Intensive Care Med 2004; 30:1615-24.
142. Hursting MJ, Dubb J, Verme-Gibboney CN. Argatroban anticoagulation in paediatric patients: a literature analysis. J Pediatr Hematol Oncol 2006; 28:4-10.
143. Young G, Tarantino MD, Wohrley J, Weber LC, Belvedere M, Nugent DJ. Pilot dose-finding and safety study of bivalirudin in infants<6 months of age with thrombosis. J Thromb Haemost 2007; 5:1654-9.
144. Martins HS, Scalabrini-Neto A, Velasco IT. Dabigatran versus enoxaparin after total hip replacement. Lancet 2007; 370:2002-3.
145. Linkins LA, Weitz JI. New anticoagulants. Semin Thromb Hemost 2003; 29:619-31.
146. Mason AR, McBurney PG, Fuller MP, Barredo JC, Lazarchick J. Successful use of fondaparinux as an alternative anticoagulant in a 2-month-old infant. Pediatr Blood Cancer 2008; 50:1084-5.
147. Büller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, et al . Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007; 357:1094-104.
148. Büller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, et al . Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 2007; 357:1105-12.
149. Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, et al . Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation 2007; 116:180-7.
150. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007; 5:2368-75.
151. Prandoni P, Lensing AWA, Cogo A, Cuppini S, Villalta S, Carta M, et al . The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125:1-7.
152. Monagle P, Adams M, Mahoney M, Ali K, Barnard D, Bernstein M, et al . Outcome of paediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr Res 2000; 47:763-6.
153. Choi M, Massicotte MP, Marzinotto V, Chan AK, Holmes JL, Andrew M. The use of alteplase to restore patency of central venous lines in paediatric patients: a cohort study. J Pediatr 2001; 139:152-6.
154. Andrew M. Epidemiology of venous thromboembolic events. In Andrew M, Monagle P, Brooker L (eds), Thromboembolic Complications During Infancy and Childhood, 1st edn. BC Decker, Hamilton, ON, 2000, pp. 111-46.
155. Press OW, Ramsey PG, Larson EB, Fefer A, Hickman RO. Hickman catheter infections in patients with malignancies. Medicine 1984; 63:189-200.
156. van Rooden CJ, Schippers EF, Barge RMY, Rosendaal FR, Guiot HFL, van der Meer FJM, et al . Infectious Complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study. J Clin Oncol 2005; 23:2655-60.
157. Kuhle S, Koloshuk B, Marzinotto V, Bauman M, Massicotte P, Andrew M, et al . A cross-sectional study evaluating post-thrombotic syndrome in children. Thromb Res 2003; 111:227-33.
158. Janssen MCH, Wollersheim H, van Asten WN, de Rooij MJ, Nov́akov́a IR, Thien Th. The post-thrombotic syndrome: a review. Phlebology 1996; 11:86-94.
159. Prandoni P, Lensing AW, Prins MH, Frulla M, Marchiori A, Bernardi E, et al . Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med 2004; 141:249-56.
160. Goldenberg NA, Knapp-Clevenger R, Manco-Johnson MJ. Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children. N Engl J Med 2004; 351:1081-8.
161. Brandjes DPM, Büller HR, Heijboer H, Huisman MV, de Rijk M, Jagt H, et al . Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997; 349:759-62.
162. van Ommen CH, Peters M. A new diagnosis in children: the post-thrombotic syndrome. Progr Pediatr Cardiol 2005; 21:23-9.
163. Massicotte MP, Dix D, Monagle P, Adams M, Andrew M. Central venous catheter related thrombosis in children: analysis of the Canadian Registry of Venous Thromboembolic Complications. J Pediatr 1998; 133:770-6.
164. Gurgey A, Aslan D. Outcome of noncatheter-related thrombosis in children: influence of underlying or coexisting factors. J Pediatr Hematol Oncol 2001; 23: 159-64.
165. Ḧausler M, Hübner D, Delhaas T, Mühler EG. Long term complications of inferior vena cava thrombosis. Arch Dis Child 2001; 85:228-33.
166. Manco-Johnson MJ, Nuss R, Hays T, Krupski W, Drose J, Manco-Johnson ML. Combined thrombolytic and anticoagulant therapy for venous thrombosis in children. J Pediatr 2000; 136:446-53.
167. van Ommen CH, Ottenkamp J, Lam J, Brennickmeier M, Heijmans HS, Büller HR, et al . The risk of postthrombotic syndrome in children with congenital heart disease. J Pediatr 2002; 141:582-6.